Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 4 PART I, 1997, Pages 1190-1196

  Bisgaard, Hans ^a   Pedersen, Svend Stenvang ^a   Nielsen, Kim Gjerum ^a   Skov, Marianne ^a   Laursen, Eva Mosfeldt ^a   Kronborg, Gitte ^a   Reimert, Claus Michael ^a   Høiby, Niels ^a   Koch, Christian ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; GLUCOCORTICOID; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; BRONCHITIS; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; INFECTIOUS COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; LUNG INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; BRONCHOPNEUMONIA; BUDESONIDE; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; FORCED EXPIRATORY FLOW RATES; HISTAMINE; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; TREATMENT OUTCOME;

EID: 0030821195     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.4.9612044     Document Type: Article

References (23)

1. Cantin, A. 1995. Cystic fibrosis lung inflammation: early, sustained and severe. Am. J. Respir. Crit. Care Med. 151:939-940.
2. Khan, T. Z., J. S. Wagener, T. Boat, J. Martinez, F. J. Accurso, and D. W. H. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082.
3. Konstan, M. W., K. A. Milliard, T. M. Norvell, and M. Berger. 1994. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 150:448-454.
4. Koch, C., and N. Høiby. 1993. Pathogenesis of cystic fibrosis. Lancet 341: 1065-1069.
5. Konstan, M. W., P. J. Byard, C. L. Hoppel, and P. B. Davies. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332:848-854.
6. Auerbach, H. S., M. Williams, J. A. Kirkpatrick, and H. R. Colten. 1985. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2:686-688.
7. Eigen, H., B. J. Rosenstein, S. FitzSimmons, and D. V. Schidlow. 1995. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J. Pediatr. 126:515-523.
8. Rosenstein, B. J., and H. Eigen. 1991. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics 87:245-246.
9. Høiby, N., E. W. Flensborg, B. Beck, B. Friis, S. V. Jacobsen, and L. Jacobsen. 1977. Pseudomonas aeruginosa infection in cystic fibrosis: diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand. J. Respir. Dis. 58:65-79.
10. Sherrill, D. L., M. D. Lebowitz, R. J. Knudson, and B. Burrows. 1992. Continuous longitudinal regression equations for pulmonary function measures. Eur. Respir. J. 5:452-462.
11. 20 comparison of linear and logarithmic interpolation. Chest 84:505-506.
12. Kronborg, G., M. B. Hansen, M. Svenson, A. Fomsgaard, N. Høiby, and K. Bendtzen. 1993. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr. Pulmonol. 15: 292-297.
13. Desch, C. E., N. L. Kovach, W. Present, C. Bryles, and J. M. Harlan. 1989. Production of human tumour necrosis factor from whole blood ex vivo. Lymphokine Res. 8:141-146.
14. Høiby, N. 1977. Pseudomonas aeruginosa infection in cystic fibrosis: diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by crossed immunoelectrophoresis: a survey. Acta Pathol. Microbiol. Scand. 262(Suppl.):1-96.
15. Pedersen, S. S., F. Espersen, and N. Høiby, 1987. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin. Microbiol. 25:1830-1836.
16. Reimert, C. M., P. Venge, A. Kharazmi, and K. Bendtzen. 1991. Detection of eosinophilic cationic protein (ECP) by an enzyme-linked immunosorbent assay. J. Immunol. Methods 138:285-290.
17. Frederiksen, B., S. Lanng, C. Koch, and N. Høiby. 1996. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21:153-158.
18. Greally, P., M. J. Hussain, D. Vergani, and J. F. Price. 1994. Interleukin-1α, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch. Dis. Child. 71:35-39.
19. Toogood, J. H. 1989. High-dose inhaled steroid therapy for asthma. J. Allergy Clin. Immunol. 83:528-536.
20. Lipworth, B. J. 1995. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110.
21. Jensen, T., S. S. Pedersen, S. Garne, C. Heilmann, N. Høiby, and C. Koch. 1987. Colistin inhalation therapy in cystic fibrosis with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19: 831-838.
22. Regelmann, W. E., G. R. Elliott, J. Warwick, and C. C. Clawson. 1990. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141:914-921.
23. Schiotz, P. O., M. Jørgensen, E. W. Flensborg, O. Faerø, S. Husby, N. Høiby, S. V. Jacobsen, H. Nielsen, and S. E. Svehag. 1983. Chronic Peudomonas aeruginosa lung infection in cystic fibrosis. Acta Paediatr. Scand. 72:283-287.